Antengene Announces Exclusive License Agreement with MPM BioImpact-Established K2 Therapeutics for ATG-106 and Option for Undisclosed Bispecific TCE
ATG-106 is a first-in-class CDH6 x CD3 bispecific T cell engager (TCE) in preclinical development for the treatment of solid tumors K2 Therapeutics, established by MPM BioImpact, obtains exclusive global rights to develop and commercialize ATG-106 outside Greater China Antengene receives upfront and near-term considerations of approximately USD 20 million for ATG-106;...
LOTTE Biologics Completes Construction of Songdo Bio Campus Plant 1 and Obtains Approval for Use
INCHEON, South Korea and SAN DIEGO, June 22, 2026 /PRNewswire/ -- LOTTE Biologics announced that it has completed major construction and obtained approval for use for Plant 1 at its Songdo Bio Campus in Incheon, South Korea. LOTTE Biologics Songdo Bio Campus Factory 1 The milestone was achieved...
Murj® Expands Global Footprint with Commercial Launch in Australia and New Zealand
SYDNEY and AUCKLAND, New Zealand, June 22, 2026 /PRNewswire/ -- Murj®, a cardiac device management software company, today announced its official expansion into the Australian market alongside broader availability for New Zealand. Following its exhibition at the recent CSANZ / HRS Advances in Pacing and Conduction System Pacing Summit in Melbourne,...
Pope Leo XIV embraces paediatric patients at CNAO in Pavia
PAVIA, Italy, June 20, 2026 /PRNewswire/ -- The National Center for Oncological Hadrontherapy (CNAO) served as the first stop today during Pope Leo XIV's pastoral visit to the city of Pavia. His choice to begin his journey at this center reflects a profound commitment to fostering meaningful dialogue between advanced scientific...
Statement on Novogene Erroneously Listed on 1260H List
BEIJING, June 20, 2026 /PRNewswire/ -- On June 8, 2026, the U.S. Department of Defense (DOD) erroneously designated Novogene Co., Ltd. on its Section 1260H list under the National Defense Authorization Act for Fiscal Year 2021. This designation is factually incorrect. Novogene is an independent, publicly listed enterprise with no state ownership or control. We are not a...
Seoul National University Hospital to Expand Global K-Bio Collaboration at BIO USA 2026
SAN DIEGO and SEOUL, South Korea, June 19, 2026 /PRNewswire/ -- Seoul National University Hospital (SNUH) will take a major step toward expanding K-Bio's global presence and international collaboration at BIO International Convention 2026 (BIO USA), the world's largest biotechnology industry event. Through its participation, SNUH aims to support promising bio startups, showcase its research capabilities in digital...
INTCO Medical Showcases Medical Consumables, Rehabilitation Medical Equipment and Physical Therapy Solutions at WHX Miami 2026
MIAMI, June 19, 2026 /PRNewswire/ -- INTCO Medical ("INTCO" or "the Company"), a leading global manufacturer of disposable gloves, is showcasing its medical consumables, rehabilitation medical equipment and physical therapy solutions at World Health Expo (WHX) Miami 2026, taking place from June 17 to 19 in Florida. The company is highlighting a range of disposable glove products, including Syntex™ Synthetic...
Wellness Innercell Expands into Indonesia Through Surabaya Representative Office Partnership
SEOUL, South Korea, June 19, 2026 /PRNewswire/ -- Wellness Innercell, a healthcare company specializing in health supplements and beauty products, announced that it has signed a representative office partnership agreement in Surabaya, Indonesia, marking a significant step toward expanding its presence in the Southeast Asian market. The agreement will run from March 1, 2026, to February 28, 2027,...
Innoscience’s current products are not affected by both rulings of the Munich Regional Court
MUNICH, June 19, 2026 /PRNewswire/ -- Innoscience today announced that the Munich Regional Court has just issued a pair of rulings, from which it could be confirmed that Innoscience's currently marketed gallium nitride ("GaN") power device products fall outside the scope of Infineon's asserted German patents and may be commercialized in Germany without restriction. These rulings are fully...
Mabwell Presents Clinical Results of Nectin-4-Targeting ADC 9MW2821 at 2026 ESMO Gynaecological Cancers Congress
SHANGHAI, June 18, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, presented two latest clinical study results of its independently developed Nectin-4-targeting ADC 9MW2821 (Bulumtatug Fuvedotin, BFv) in cervical cancer at the European Society for Medical Oncology Gynaecological Cancers Congress 2026 (ESMO Gynae 2026) in Copenhagen, Denmark, held June 17–19, 2026. The two...
